Introduction 23
Chronic kidney disease (CKD) is considered a complex phenotype with a 24 genetic predisposition 1 . Previous GWAS have successfully identified multiple 25 common genetic risk variants associated with the CKD-defining measures of 26 estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio 27 (UACR). [2] [3] [4] [5] Together, these variants explain only a small proportion of the 28 variation in eGFR and UACR. 6 To comprehensively interrogate protein-coding 29 regions and assess the effects of rare variants (minor allele frequency 30
[MAF]<1%), we carried out a two-stage meta-analysis of the association between 31 eGFRcrea and variants genotyped on the Illumina HumanExome chip 32
[http://genome.sph.umich.edu/wiki/Exome_Chip_Design] among 111666 33
European ancestry (EA) participants from the CKDGen Consortium and 34 assessed the role of genes significantly associated with eGFRcrea in kidney 35 development using embryonic zebrafish models. In secondary analyses, we 36 examined associations with eGFRcrea stratified by diabetes status, and in a 37 smaller subset of EA participants, we also tested estimated glomerular filtration 38 rate based on cystatin C (eGFRcys) and UACR. An additional 9624 participants 39 of African ancestry (AA) were also used in an independent exome-chip discovery 40 meta-analysis. 41
42

Results
43
Up to 120357 participants from 27 studies of EA and up to 11386 44 participants from 7 studies of AA were included in Stage 1 analyses for 45 eGFRcrea, eGFRcys, or UACR. An additional 48343 participants from 12 46 studies of EA were included in Stage 2 analysis of eGFRcrea. All participants 47 provided informed consent and each of the studies were approved by its 48 governing ethics committee or Institutional Review Boards. Sample 49 characteristics and genotyping information for each study are summarized in 50
Supplementary Tables 1 and 2 . 51
In Stage 1 single-variant EA analyses, we identified 33 loci associated 52 with eGFRcrea (Table 1 and Supplementary Table 3 ) that met our a priori chip-53 wide significance threshold of P<3.7x10 -7 (0.05/134299 variants). Of these, 8 had 54 not been identified in association with eGFRcrea from previous GWAS analyses; 55 6 were missense variants -rs34611728 (PPM1J), rs78444298 (EDEM3), 56 rs11553746 (ACP1), rs2307394 (ORC4), rs55760516 (SPEG), and rs9493627 57 (EYA4) -and 2 were GWAS tag SNPs included on the exome chip due to prior 58 associations in the NHGRI GWAS Catalog for caffeine/coffee intake 7, 8 -59 rs2472297 (intergenic, near CYP1A1) and inflammatory bowel disease 9 -60
rs8049439 (intronic, ATXN2L); all were common variants (MAF>1%). A 61
Manhattan plot displaying all 33 chip-wide significant loci is shown in Figure. 
. 66
In Stage 2 analyses, we followed up the 8 newly identified eGFRcrea loci 67 meeting our significance threshold among an additional 48343 EA participants 68 from 12 studies (sample characteristics and genotyping information are 69 summarized in Supplementary Tables 2 and 4 ). All loci but ORC4 met criteria for 70 replication (a direction of effect consistent with Stage 1 analysis, a P 1-sided <0.05 71 from Stage 2 analysis, and P<3.7x10 -7 from a combined Stage 1 and Stage 2 72 analysis, Table 1 ). Because diabetes mellitus is a major risk factor for CKD, we 73 assessed the genetic associations at these loci in the presence or absence of 74 diabetes to obtain additional insights into potential mechanistic pathways. In 75 total, 11040 and 94677 participants were included in the diabetes stratified and 76 non-diabetes stratified analyses, respectively. In analyses stratified by diabetes 77 status, the beta-coefficients were directionally consistent and of similar 78 magnitude between the strata for 6 out of 7 newly identified loci (Supplementary 79 Table 6 ). Common variants at SLC47A1 and LRP2 have been previously 95 reported in association with eGFRcrea, 4, 6 thus implicating both rare and common 96 variants at both loci. 4, 6 Conversely, the association with SOS2 was novel 97 (P SKAT =5.38x10 -8 ; P T1 =3.25x10 -6 ). No genes reached the threshold for chip-wide 98 significance in gene-based associations for eGFRcrea stratified by diabetes 99 status, eGFRcys, or UACR. 100
To identify genes that may play a role during kidney development, we 101 used knockdown zebrafish embryos generated by injecting morpholino 102 oligonucleotides (MOs) into single-cell stage embryos. Morpholinos are a 103 commonly used tool in zebrafish screens because they enable an efficient 104 identification of genes that may have a role in developmental processes. The 105 morpholinos targeted genes with non-synonymous variants (ppmj1, acp1, eya4, 106 speg, and edem3) and the novel gene-based finding, sos2 (Supplemental Figure  107 5A). General defects in the pronephros or embryonic kidney structure (marked 108 by expanded pax2a expression) were observed in acp1 ATG MO-and sos2 ATG 109 MO-injected embryos compared to controls ( Figure. 2, panels A, E and I; 110 P<0.0001 for both). Both acp1 ATG-and sos2 ATG-knock-downs showed 111 elongated proximal tubules (increased slc20a1a expression) compared to the 112 control group (Figure. 2, panels B, F and J; mean difference in proximal tubule 113 length: sos2=81.7 µm; P<0.0001 and acp1= 74.7 µm; P<0.0001, panel M). The 114 increase in proximal tubule length was not a consequence of increased embryo 115 length, as both sos2 ATG and acp1 ATG-morphants had significantly reduced 116 body length relative to controls (Supplementary Figure 5B) . Additionally, acp1 117 ATG-knockdowns showed shorter distal tubule length (slc12a3 expression), 118 which may be a consequence of reduced body length ( Figure. 2, panels C, G and 119 K; P<0.0001). No abnormalities were observed for podocytes (wt1a expression) 120 for sos2 or acp1 compared to controls (Figure. 2, panels D, H and L; P>0.05) . 121
Due to the potential off target effects of morpholinos, these developmental 122 findings were validated with secondary splice-site morpholinos designed to target 123 the sos2 and acp1 pre-mRNA (Supplementary Figure 5A) . The sos2 and acp1 124 splice morpholino-injected embryos had significantly increased proximal tubule 125 length relative to controls (Supplementary Figure 5C-E) . Furthermore, the acp1 126 splice-site morpholino injected embryos had shortened distal tubules (slc12a3 127 expression) consistent with the phenotype induced by the ATG morpholino 128 (Suppementary Figure 5F ). The reproducibility of the proximal tubule 129 developmental defects with ATG and splice-site morpholinos adds confidence to 130 the specificity of the morpholino-induced tubule phenotype. 131
Follow-up in situ hybridization experiments to determine expression 132 patterns of sos2 and acp1 during zebrafish development did not reveal kidney-133 specific expression of sos2 or acp1; however, sos2 and acp1 were broadly 134 expressed throughout embryogenesis at key stages of kidney development and 135 may be acting to control kidney development (Supplementary Figure 6) . In 136 humans, both sos2 and acp1 protein are detected in adult renal tubules 10 . No 137 significant developmental abnormalities were observed among MO knockdowns 138 for the remaining genes (Supplementary Figure 6C) . These findings suggest that 139 both SOS2 and ACP1 may influence embryonic renal development, and that 140 genetic influences on kidney development may contribute to variation in kidney 141
function. 142
We next sought to determine whether sos2 and acp1-mediated 143 developmental alterations led to abnormalities in kidney function. In zebrafish, 144 edema is a common sign of kidney failure 11 . We first performed an edema 145 prevalence study and identified incidence rates of pericardial and global edema 146 in sos2 and acp1 morphant larva. Both sos2 and acp1 ATG morpholino injected 147 embryos had a heightened incidence of pericardial edema beginning at 72 hpf 148 We also evaluated heart rate in the sos2 and acp1 morphants relative to 166 controls because compromised cardiovascular function could contribute to 167 defects in dextran clearance. At 96 hours post fertilization (24 hours after dextran 168 injection), the sos2 (145.5 ± 3.854 bpm; p = 0.0028) and acp1 (151.2 ± 2.653 169 bpm; p < 0.0001) morphants had an elevated mean heart rate relative to controls 170 (127.8 ± 3.353 bpm) (Supplementary Figure 2G) . While altered kidney 171 development, abnormal tubular structure, edema, and decreased dextran 172 clearance all support the conclusion that both sos2 and acp1 are regulators of 173 kidney development and function, it remains possible that altered hemodynamics 174 contribute to the edema and dextran clearance phenotypes observed. 175
In separate single variant analyses among 9624 AA participants, we 176 identified 3 loci in association with eGFRcrea at chip-wide significance 177 (Supplementary Table 8 , P<3.7x10 -7 ). These variants were rare and the limited 178 availability of AA cohorts prevented replication of these findings. The APOL1 G1 179 variant, rs73885319, that were known risk factor for kidney function decline and 180 end-stage renal disease in African Americans, was included on the exom array. 181
However, it is not associated with eGFRcrea in the AA participants here (P=0.70). 182
To investigate if the newly identified eGFRcrea loci were also associated 183 with diabetes mellitus and arterial hypertension, major risk factors for CKD, we 184 tested for associations between the 7 validated eGFRcrea loci with blood 185 pressure and type 2 diabetes among EA participants in collaborations with the 186 CHARGE Blood Pressure 13 and CHARGE Glycemia-Type 2 Diabetes 14 Working 187
Groups. Consistent with prior observations, the majority of variants were not 188 associated with blood pressure traits or diabetes (Supplementary Table 9 ). The 189 exception was rs2472297 at the CYP1A1 locus, a GWAS tag SNP previously 190 associated with coffee/caffeine intake 7, 8 . This SNP was also associated with 191 systolic and diastolic blood pressure (P=7.4x10 -7 , and 4.6x10 -11 , respectively). 
211
The SOS2 protein is expressed in the glomeruli and tubules of kidneys from adult 212 humans 10 . Together, these findings provide further evidence for a potential role 213
for SOS proteins in kidney development and function. There are no prior reports 214 of an association between kidney function and ACP1, a gene that encodes for an 215 acid phosphatase involved in the immune response and found in erythrocytes. 19 
216
Our observations of kidney abnormalities in sos2-and acp1-knockdowns provide 217 genes and target tissues for prioritization in future studies of more extensive 218 functional follow-up, diagnostic screening and potentially drug development. 219
Although morpholinos are an efficient tool for the rapid evaluation of 220 GWAS hits, they have the potential for off-target effects, and morphant 221 phenotypes are not always recapitulated in genetic mutant models. In this study, 222
we evaluated sos2 and acp1 kidney development phenotypes using two 223 independent morpholinos, which we believe adds confidence in the specificity of 224 our phenotypes. Furthermore, we provided evidence that kidney developmental 225 changes correlate with edema and reduced dextran clearance from the blood. 226
We believe that our morpholino screen has allowed us to clarify promising 227 candidates for further study. Simultaneously, we acknowledge that future studies 228 in genetic mutants will enhance and clarify these findings. Since genetic 229 knockout techniques do not necessarily recapitulate exact features of the 230 identified human variants, future experiments are also needed to evaluate the 231 impact of specific variants on kidney development and function. 232
The majority of identified novel variants were common. The strongest 233 single-variant association with eGFRcrea to date is the common variant 234 rs13329952 at the UMOD locus with an effect size of 0.016 ln(ml/min/1.73 m 2 ) 235 (MAF=0.19). 15 Given our large discovery sample, our study was adequately 236 powered (>80%) to detect effect sizes of 0.11 to 0.008 ln(ml/min/1.73 m 2 ) for very 237 rare variants to more common variants (0.0005>MAF>0.10) (details of the power 238 calculation can be found in Supplementary Methods). While the selection of non-239 synonymous content was expected to enrich for functional variants with large 240 effect sizes, a possible reason for the lack of these findings might be the design-241 based, limited coverage of rare variants on the exome chip. The exome chip was 242 primarily designed to assess nonsynonymous rare variants that had been 243 observed among ~12,000 sequenced participants that were not selected based 244 on kidney disease (http://genome.sph.umich.edu/wiki/Exome_Chip_Design), and 245 thus, we would not expect kidney disease causing mutations to be well 246 represented on the exome chip. While the convenience and low cost of a chip-247 based genotyping array focused on exonic variants were influential in facilitating 248 a large number of cohorts to participate needed for a well-powered study, the 249 limited coverage of the exome impacted the ability of both single-variant and 250 gene-based tests to assess all exonic variation in association with kidney 251 function. Thus, we cannot rule out bona fide rare variant associations with 252 eGFRcrea. Large-scale whole exome or whole genome sequencing will be able 253 to adequately address the unresolved issue of the contribution of rare variants to 254 the variation of kidney function in the general population. Due to limited sample 255 size in the diabetes stratum compared to the non-diabetes stratum, we did not 256 have adequate power to assess unique genetic associations in the diabetes 257 stratified analysis. We did not implement a random effects meta-analysis as an 258 alternative screening procedures for novel loci because the between-study 259 heterogeneity was small. The analysis module that we used cannot correctly 260 account for the different allele dosage between women and men and therefore 261
we were unable to implement association analysis for chromosome X variants. 262
While our study supports the observation that gene-based analyses aggregating 263 rare non-synonymous variants are able to identify new loci in association with 264 common complex phenotypes 14, [20] [21] [22] and can additionally uncover new rare 265 missense variants within known loci, the number of loci identified through gene-266 based methods remains a small minority of the findings compared to single-267 variant results. Finally, the zebrafish knockdowns helped us to screen novel loci 268 that appear to have a role in kidney development or function. However, 269 extrapolation of the relationship between our novel loci among patients with more 270 advanced CKD remains to be determined; follow up studies are needed to 271 assess the association of these loci with end-stage renal disease and incident 272
CKD. 273
In summary, we identified 8 novel loci (7 common single variants and 1 274 gene with multiple rare coding variants) associated with kidney function. 275
Functional experiments in zebrafish highlighted potential roles for SOS2 and 276 ACP1 in embryonic kidney development. Future whole exome and whole 277 genome sequencing studies will be needed to assess the full spectrum of rare 278 genetic variants on kidney function. 279
280
Concise Methods 281
Study Participants 282
Across all traits analyzed, a total of 120357 participants from 27 studies of 283
European ancestry (EA) were included in Stage 1 of this study. An additional 284 48343 participants from 12 studies of EA were included in Stage 2. A total of 285 11386 participants from 7 studies of African ancestry (AA) were also included in 286 separate analyses. Study-specific characteristics are summarized in 287
Supplementary Table S1, S2 and S4. All participants provided informed consent 288 and each study was approved by its governing ethics committee or Institutional 289
Review Board. 290
291
Phenotype Definitions 292
Serum creatinine was measured in each study as described in the Study-293 Specific Methods section in the Supplemental Material, and calibrated to the 294 National Health and Nutrition Examination Study (NHANES) data to account for 295 between-laboratory variation.
23, 24 eGFR based on serum creatinine (eGFRcrea) 296 was estimated using the four-variable MDRD Study Equation.
25 Cystatin C, an 297 alternative biomarker of kidney function, was measured in a sub-set of 298 participating studies. eGFR based on cystatin C (eGFRcys) was estimated as 299 76.7x(serum cystatin C).
25 All eGFRcrea and eGFRcys values <15 300 ml/min/1.73m 2 were set to 15, and those >200 ml/min/1.73m 2 were set to 200 to 301 avoid undue influence from outliers. UACR was defined as urinary albumin 302 (mg/L) / urinary creatinine (mg/dl)]*100. All analyzed traits (eGFRcrea, eGFRcys, 303 and UACR) were natural log (ln)-transformed. Diabetes was defined as fasting 304 glucose ≥126 mg/dl, pharmacologic treatment for diabetes, or by self-report. 305
Hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic 306 blood pressure ≥90 mmHg or pharmacologic treatment for hypertension. Korcula and GS applied the cluster file from the CHARGE Consortium for 320 genotype calling. Details regarding genotyping and quality control within each 321 study are summarized in Supplementary Table S2 . 322
323
Statistical methods for Stage 1 324
By following a centralized analysis plan, each study performed two sets of 325 analyses: single-variant analysis and gene-based analysis. The primary meta-326 analyses were focused on the EA population and a secondary set of meta-327 analyses were focused on the AA population due to a substantially smaller 328 sample size. Where not specified otherwise, R software was used for data 329 management, statistical analyses and graphing. 
Single-variant analysis 332
Each study performed association analyses of the following phenotypes 333 and models: 1) ln-transformed eGFRcrea, 2) ln-transformed eGFRcys, 3) ln-334 transformed UACR and 4) ln-transformed eGFRcrea stratified by diabetes status. 335
These association analyses were based on linear regression models adjusting 336 for age, sex, study site (if applicable), family structure (if applicable), and the first 337 10 principal components to control for population stratification. All analyses were 338 performed assuming an additive genetic effect and all analyses were stratified by 339
ancestry. 340
For single-variant meta-analysis, study-specific results were combined for 341 each trait in a fixed-effects model using METAL. 29 We restricted single-variant 342 meta-analyses to 1) autosomal variants; 2) polymorphic variants; 3) variants 343 existing in the joint calling effort within the CHARGE consortium; 27 and 4) with 344 minor allele count (MAC) ≥20 across all cohorts in each ancestry group. 345
Bonferroni correction for the number of variants tested within each ancestry was 346 used to set the significance threshold for each analysis (chip-wide significance), 347 corresponding to P<3. (embryonic kidney) structures were visualized using a series of established 433 markers: pax2a (global), wt1a (podocyte), slc20a1a (proximal tubule), and 434 slc13a3 (distal tubule). acp1 probe was generated from zebrafish cDNA using the 435 following primers: 5' TGGAGAATAGACAGTGCCGC 3' (forward 1) and 5' 436 TTTTCACGCTGCTTGCCTTC 3' (reverse 1), and 5' 437 GTGGAGAATAGACAGTGCCG 3' (forward 2) and 5' CAGGAAGGCTTTGCATC 438 3' (reverse 2) . sos2 probe was generated from zebrafish cDNA using the 439 following primers: 5' GTGTTCGAGGAAGGAGCACA 3' (forward) and 5' 440
TGATGTTCCACCCACTGACG 3' (reverse). 441
Abnormal gene expression patterns were identified by direct comparison 442 to control embryos that were injected with a standard control MO designed by 443 GeneTools (SynGene, Cambridge, UK). Developmental phenotypes were 444 scored by two independent researchers. Fisher's exact tests were used to test 445 for normal and abnormal embryonic phenotypes for the pax2a, wt1a and slc13a3 446 markers and Student-t test was used to test for differences in proximal tubule 447 length for the slc20a1a marker; P<0.05 was set as a threshold for statistical 448 significance. To evaluate proximal tubule length, the distance between the most 449 anterior and the most posterior tip of the right proximal tubule (from standardized 450 dorsal-view images) was measured using the imageJ measurement tool. Fisher's 451
Exact test was used to test for differences in edema prevalence; P<0.05 was set 452 as a threshold for statistical significance. 453
Dextran clearance experiments were performed following previously 454 described protocol 12 . 72 hours after morpholino injection, embryos were 455 anesthetized in a 1:20 dilution of 4mg/ml Tricane in embryo water and placed on 456 a 2% agarose injection mold. An equal volume of tetramethylrhodamine dextran 457 (70,000 MW; Invitrogen) was injected into the cardiac sinus venosus of each 458 embryo, and individual embryos were sorted into designated wells for timelapse 459 imaging. Fluorescent microscopy images were taken at 2 hpi (74 hpf), 24 hpi (96 460 hpf), and 48 hpi (120 hpf) for each sorted embryo to assess loading fluorescence 461 and the dextran clearance over time. Fluorescence intensity in the cardiac region 462 was measured as the mean grayscale value using Image J as previously 463 
891
Abbreviations: EA = effect allele, EAF = effect allele frequency, Chr = chromosome, SE = standard error, P= p-value, 
907
Abbreviations: Chr = chromosome, cMAF = cumulative minor allele frequency used in analysis, SE = standard error, P= p-value 908 909 910 911 
